GRIFOLS ADR 1/2/EO-50 (G0F) - Total Assets
Based on the latest financial reports, GRIFOLS ADR 1/2/EO-50 (G0F) holds total assets worth €19.71 Billion EUR (≈ $23.05 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore G0F long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
GRIFOLS ADR 1/2/EO-50 - Total Assets Trend (2021–2025)
This chart illustrates how GRIFOLS ADR 1/2/EO-50's total assets have evolved over time, based on quarterly financial data. Check GRIFOLS ADR 1/2/EO-50 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
GRIFOLS ADR 1/2/EO-50 - Asset Composition Analysis
Current Asset Composition (December 2025)
GRIFOLS ADR 1/2/EO-50's total assets of €19.71 Billion consist of 25.7% current assets and 74.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.1% |
| Accounts Receivable | €651.00 Million | 3.3% |
| Inventory | €3.30 Billion | 16.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.73 Billion | 13.8% |
| Goodwill | €6.83 Billion | 34.7% |
Asset Composition Trend (2021–2025)
This chart illustrates how GRIFOLS ADR 1/2/EO-50's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of GRIFOLS ADR 1/2/EO-50.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GRIFOLS ADR 1/2/EO-50's current assets represent 25.7% of total assets in 2025, a decrease from 28.7% in 2021.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2025, up from 3.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 40.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 34.7% of total assets.
GRIFOLS ADR 1/2/EO-50 Competitors by Total Assets
Key competitors of GRIFOLS ADR 1/2/EO-50 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX114.07 Billion |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357
|
China | CN¥2.89 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
GRIFOLS ADR 1/2/EO-50 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.51 | 2.66 | 1.68 |
| Quick Ratio | 0.88 | 1.01 | 0.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.06 Billion | €3.57 Billion | €2.80 Billion |
GRIFOLS ADR 1/2/EO-50 - Advanced Valuation Insights
This section examines the relationship between GRIFOLS ADR 1/2/EO-50's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.12 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -7.9% |
| Total Assets | €19.71 Billion |
| Market Capitalization | $4.21 Billion USD |
Valuation Analysis
Below Book Valuation: The market values GRIFOLS ADR 1/2/EO-50's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: GRIFOLS ADR 1/2/EO-50's assets decreased by 7.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GRIFOLS ADR 1/2/EO-50 (2021–2025)
The table below shows the annual total assets of GRIFOLS ADR 1/2/EO-50 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €19.71 Billion ≈ $23.05 Billion |
-7.91% |
| 2024-12-31 | €21.41 Billion ≈ $25.02 Billion |
+1.97% |
| 2023-12-31 | €20.99 Billion ≈ $24.54 Billion |
-1.12% |
| 2022-12-31 | €21.23 Billion ≈ $24.82 Billion |
+10.38% |
| 2021-12-31 | €19.23 Billion ≈ $22.49 Billion |
-- |
About GRIFOLS ADR 1/2/EO-50
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more